Clinical studies suggest that by month three, users can lose about 5-10% of their starting body weight, especially when combining semaglutide with a balanced diet and exercise
Date: June 6, 2026 Source: University of Pennsylvania School of Medicine Summary: A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop breast cancer
Natural GLP-1 cannot be used therapeutically because it is rapidly degraded by the enzyme DPP-4 within 1-2 minutes, requiring continuous intravenous infusion for sustained effect
Epithalon Peptide and Cancer Cells In this study, (9) one-year-old female (C3H/He) mice with tumors on the reproductive organs (mammary glands and ovaries) were observed
10.1186/s12974-017-1004-5 79 NeherJ